B. Riley Reiterates “Neutral” Rating for CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics (NASDAQ:CBAYGet Free Report)‘s stock had its “neutral” rating reaffirmed by investment analysts at B. Riley in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $32.50 target price on the biopharmaceutical company’s stock, up from their prior target price of $29.00. B. Riley’s price objective indicates a potential upside of 0.90% from the stock’s previous close.

CBAY has been the topic of a number of other reports. Raymond James cut CymaBay Therapeutics from an “outperform” rating to a “market perform” rating and set a $32.50 target price on the stock. in a research note on Tuesday. William Blair cut CymaBay Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. Piper Sandler raised their price target on CymaBay Therapeutics from $19.00 to $33.00 and gave the company an “overweight” rating in a report on Monday, November 6th. StockNews.com lowered CymaBay Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 8th. Finally, Lifesci Capital reissued an “outperform” rating on shares of CymaBay Therapeutics in a report on Tuesday, December 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, CymaBay Therapeutics currently has an average rating of “Hold” and a consensus price target of $25.45.

Get Our Latest Stock Analysis on CymaBay Therapeutics

CymaBay Therapeutics Stock Performance

CBAY stock opened at $32.21 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 22.76 and a current ratio of 22.76. The stock has a market capitalization of $3.65 billion, a price-to-earnings ratio of -35.01 and a beta of 0.28. CymaBay Therapeutics has a 1 year low of $7.26 and a 1 year high of $32.24. The stock’s fifty day moving average is $23.11 and its two-hundred day moving average is $17.82.

Insider Buying and Selling

In related news, General Counsel Paul T. Quinlan sold 5,000 shares of CymaBay Therapeutics stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $17.38, for a total value of $86,900.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, VP Daniel Menold sold 21,497 shares of CymaBay Therapeutics stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $21.99, for a total value of $472,719.03. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Paul T. Quinlan sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $17.38, for a total value of $86,900.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 164,439 shares of company stock valued at $3,470,441. 7.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CymaBay Therapeutics

A number of institutional investors have recently bought and sold shares of CBAY. Raymond James & Associates boosted its position in CymaBay Therapeutics by 26.3% during the 1st quarter. Raymond James & Associates now owns 97,604 shares of the biopharmaceutical company’s stock worth $304,000 after acquiring an additional 20,337 shares during the period. Bank of New York Mellon Corp boosted its position in CymaBay Therapeutics by 8.6% during the 1st quarter. Bank of New York Mellon Corp now owns 276,766 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 21,961 shares during the period. MetLife Investment Management LLC acquired a new stake in CymaBay Therapeutics during the 1st quarter worth about $163,000. BlackRock Inc. boosted its position in CymaBay Therapeutics by 2.7% during the 1st quarter. BlackRock Inc. now owns 5,466,209 shares of the biopharmaceutical company’s stock worth $16,998,000 after acquiring an additional 142,081 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in CymaBay Therapeutics by 18.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 940,806 shares of the biopharmaceutical company’s stock worth $2,926,000 after acquiring an additional 145,965 shares during the period. 95.03% of the stock is currently owned by institutional investors and hedge funds.

CymaBay Therapeutics Company Profile

(Get Free Report)

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC).

Featured Stories

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.